Compare EVTC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | TYRA |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2021 |
| Metric | EVTC | TYRA |
|---|---|---|
| Price | $29.36 | $36.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $35.80 | ★ $47.50 |
| AVG Volume (30 Days) | 270.3K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $6.86 | N/A |
| P/E Ratio | $13.83 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $24.95 | $8.75 |
| 52 Week High | $38.56 | $40.65 |
| Indicator | EVTC | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 52.57 |
| Support Level | $28.83 | $34.01 |
| Resistance Level | $30.25 | $39.90 |
| Average True Range (ATR) | 0.80 | 1.87 |
| MACD | 0.12 | -0.11 |
| Stochastic Oscillator | 40.34 | 43.77 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.